Association Between Migraine Comorbidity and Psychiatric Symptoms Among People With Newly Diagnosed Focal Epilepsy
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Objective:
Little is known about psychiatric symptoms among patients with migraine and newly diagnosed focal epilepsy. The investigators compared symptoms of depression, anxiety, and suicidality among people with newly diagnosed focal epilepsy with migraine versus without migraine.
Methods:
The Human Epilepsy Project is a prospective multicenter study of patients with newly diagnosed focal epilepsy. Depression (measured with the Center for Epidemiologic Studies Depression Scale), anxiety (measured with the 7-item Generalized Anxiety Disorder scale), and suicidality scores (measured with the Columbia-Suicide Severity Rating Scale [C-SSRS]) were compared between participants with versus without migraine. Data analysis was performed with the Kolmogorov-Smirnov test for normality assessment, the Mann-Whitney U test, chi-square test, and linear regression.
Results:
Of 349 patients with new-onset focal epilepsy, 74 (21.2%) had migraine. There were no differences between the patients without migraine versus those with migraine in terms of age, race, and level of education. There were more women in the group with migraine than in the group without migraine (75.7% vs. 55.6%, p=0.0018). The patients with epilepsy and comorbid migraine had more depressive symptoms than the patients with epilepsy without migraine (35.2% vs. 22.7%, p=0.031). Patients with epilepsy with comorbid migraine had more anxiety symptoms than patients with epilepsy without migraine, but this relation was mediated by age in logistic regression, with younger age being associated with anxiety. Comorbid migraine was not associated with C-SSRS ideation or behavior.
Conclusions:
Among a sample of patients with newly diagnosed focal epilepsy, 21.2% had migraine. Migraine comorbidity was associated with higher incidence of depressive symptoms. Future studies should be performed to better assess these relationships and possible treatment implications.
Epilepsy and migraine are comorbid neurological conditions; people with epilepsy have almost double the prevalence of migraine compared with those without epilepsy (1). The conditions both consist of paroxysmal, short, and somewhat stereotyped events. They share triggers such as bright flashing lights, stress, and sleep deprivation. They might be preceded by transient neurological symptoms (aura). Both seizure and migraine attacks might be accompanied by some level of cognitive dysfunction. Seizures might be preceded, accompanied, or followed by non-migrainous headaches. Finally, comorbid psychiatric conditions are common among both populations (2, 3).
The neuropsychiatric conditions that are comorbid with both epilepsy (2) and migraine (3) have been well established. It is well known that the neuropsychiatric disorders common to these conditions can influence people’s prognosis and quality of life (2, 4–6). There is strong evidence that both the relationship between epilepsy and depression (7, 8) and the relationship between migraine and depression are bidirectional (9). For example, between attacks, patients experience fear of recurrent attack and may develop reactive symptoms of depression and anxiety (10). People with both conditions also have higher reported rates of suicidality (11, 12). However, most studies have examined the psychiatric comorbid conditions in relation to either epilepsy or migraine. Little is known about the association of the psychiatric symptoms and suicidality in patients with both conditions.
Given the paucity of knowledge about comorbid psychiatric conditions specifically among individuals with both epilepsy and migraine, the goal of this study was to compare the presence of symptoms of depression, anxiety, and suicidality among patients with newly diagnosed focal epilepsy with and without migraine. We hypothesized that psychiatric symptoms would be more common among people with focal epilepsy and migraine than among those without migraine because both migraine and epilepsy are comorbid with depression and anxiety. A higher burden of psychiatric symptoms would affect patient evaluation and management.
Methods
Participants
We used data collected for the Human Epilepsy Project (HEP) (13), a 6-year, prospective, observational, multicenter study to evaluate clinical characteristics of patients with newly treated focal epilepsy. The criteria for subjects to be included in the HEP were as follows: at least one confirmed spontaneous focal seizure and start of antiepileptic medication not more than 4 months before enrollment in the study. We included participants older than age 18. The patients were enrolled from July 18, 2012, through September 28, 2017. This study was approved by the New York University School of Medicine Institutional Review Board.
Questionnaires
All questionnaires were administered at the initial visit by study coordinators. The demographic questionnaire asked about ethnicity (Hispanic or Latino, not Hispanic nor Latino, unknown, or not reported) and race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, unknown, or not reported). Those questions were asked independent of each other.
The Center for Epidemiologic Studies Depression Scale (CES-D) is a validated questionnaire developed by Lenore Sawyer Radloff in 1977 to assess depressive symptoms among the general population using 20 questions, all ranked on 4-point scales (14, 15). A cutoff score of at least 16 was used to screen for presence of significant depressive symptomatology.
The 7-item Generalized Anxiety Disorder (GAD-7) scale consists of seven questions, all ranked on a 4-point scale. It has demonstrated validity in patients with epilepsy and patients with migraine (16, 17). A cutoff score of at least 10 was used for the GAD-7 because it has good sensitivity and specificity for screening for generalized anxiety disorder (89% and 82%, respectively), panic disorder (74% and 81%, respectively), social anxiety disorder (72% and 80%, respectively), and posttraumatic stress disorder (86% and 84%, respectively) (18).
Suicidality was assessed using the validated Columbia-Suicide Severity Rating Scale (C-SSRS) (19). In this study, an answer of “yes” to at least one of the five suicidal ideation questions was scored as a 1 for C-SSRS ideation, and an answer of “yes” to at least one of the five attempt questions was scored as a 1 for C-SSRS behavior. An answer of “yes” to either at least one ideation question or at least one attempt question was scored as a 1 for C-SSRS ideation or behavior.
Migraine was assessed using the American Migraine Prevalence and Prevention migraine assessment questionnaire (20, 21). The 13 questions for this assessment tool inquire about migraine criteria as described in the International Classification of Headache Disorders–Third Edition, such as at least five attacks following criteria 2–4; migraine lasting at least 4 hours; nausea, vomiting, or both; photophobia; and at least two of the following four characteristics: unilateral migraine, throbbing migraine, migraine of at least moderate pain intensity, and migraine aggravated by activities such as climbing stairs (22). The questionnaire also asks participants to rate the intensity of the head pain they have during their most severe headache on a scale ranging from 1 (very mild) to 10 (the worst pain).
The Migraine Disability Assessment Test (MIDAS) is a validated measure of the impact of migraine on patients’ quality of life. MIDAS scores are classified in four categories: little or no disability for scores ranging from 0 to 5, mild disability for scores ranging from 6 to 10, moderate disability for scores ranging from 11 to 20, and severe disability for scores of at least 21 (23).
Statistical Analyses
The main predictor was migraine comorbidity. The main outcomes were CES-D score ≥16, GAD-7 score ≥10, and at least one positive answer on the C-SSRS. First, data distribution was assessed for normality using the Kolmogorov-Smirnov test. Because the data set was not normally distributed, the analyses were performed using the Mann-Whitney U test, chi-square test, and linear regression. Given that age and gender are associated with migraine, anxiety, and depression, we used age and gender as covariates in the logistic regressions. There was no need for analysis of missing data because less than 10% of patients were missing some data. The participants with missing data were omitted from statistical analyses. Statistical analyses were conducted with Excel version 15.0.4833.1001 and IBM SPSS Statistics, version 22.0.0.
Results
Demographic Characteristics
Of 349 patients with new-onset focal epilepsy, 74 (21.2%) had migraine (Table 1). The proportion of women in the comorbid migraine group was markedly higher than among the group of patients without migraine (75.7% vs. 55.6%; χ2=9.75, df=1, p<0.001) (Table 1). The median age of the total sample was 36 years (mean=37.4 years [SD=12]). In the group without migraine, the median age was 36 years (range, 19–64 years; mean=37.6 years [SD=12]). In the group with migraine, the median age was 34 years (range, 19–60 years; mean=36.3 years [SD=11.9]). No difference in age was found between the patients without migraine and the patients with migraine (Mann-Whitney U test=0.36). No statistically significant differences were found between the patients without migraine and the patients with migraine in terms of race and highest level of education, (Table 1). The proportion of patients with comorbid migraine working a full-time job was lower than the group without migraine (66.2% vs. 50%; χ2=6.5, df=1, p=0.011) (Table 1). Among the 29 participants who identified as Hispanic or Latino, one identified as Black, 20 identified as White, and the rest checked the “unknown” box for the race question on the demographics questionnaire.
| All participants (N=349) | Epilepsy patients without migraine (N=275) | Epilepsy patients with migraine (N=74) | pa | ||||
|---|---|---|---|---|---|---|---|
| Characteristic | N | % | N | % | N | % | |
| Female | 209 | 59.9 | 153 | 55.6 | 56 | 75.7 | <0.001 |
| Race and/or ethnicityb | 0.69 | ||||||
| Unknown | 18 | 7.8 | 16 | 5.9 | 2 | 2.8 | |
| White | 274 | 78.5 | 216 | 78.5 | 60 | 81 | |
| Black or African American | 42 | 12 | 32 | 11.6 | 10 | 13.5 | |
| Asian | 12 | 3.4 | 10 | 3.6 | 2 | 2.7 | |
| American Indian or Alaska Native | 1 | 0.3 | 1 | 0.4 | 0 | 0 | |
| Hispanic or Latino | 29 | 8.3 | 23 | 8.4 | 6 | 8.1 | 0.89 |
| Highest level of education | 0.81 | ||||||
| Did not finish high school | 18 | 5.2 | 15 | 5.5 | 3 | 4.0 | |
| GED | 4 | 1.1 | 3 | 1.1 | 1 | 1.4 | |
| High school | 48 | 13.8 | 37 | 13.5 | 11 | 14.9 | |
| Associate’s degree | 38 | 10.9 | 32 | 11.6 | 6 | 8.1 | |
| Some college | 56 | 16.0 | 39 | 14.2 | 17 | 23.0 | |
| Bachelor’s degree | 108 | 30.9 | 85 | 30.1 | 23 | 31.1 | |
| Graduate school | 75 | 18.5 | 62 | 22.5 | 13 | 17.6 | |
| Level of employment | 0.067 | ||||||
| Full time vs. not full time | 219 | 62.8 | 182 | 66.2 | 37 | 50 | 0.011 |
| Part time | 39 | 11.2 | 29 | 10.5 | 10 | 13.5 | |
| Homemaker | 12 | 3.4 | 7 | 2.5 | 5 | 6.8 | |
| Student | 30 | 8.6 | 21 | 7.6 | 9 | 12.2 | |
| Unemployed | 45 | 12.9 | 32 | 11.6 | 13 | 17.6 | |
| Family history of seizures | 106 | 31.5 | 82 | 30.9 | 24 | 33.3 | 0.70 |
a
Chi-square test was used. Bold indicates statistical significance.
b
Some participants checked more than one racial category.
Headache Characteristics
Among the patients with migraine, the mean age at headache onset was 17.9 years (SD=8.5). The mean headache pain intensity score was 8.1 (SD=1.8). The mean MIDAS score was 10.3 (SD=19.1). More than a quarter (29.8%) of patients with migraine reported moderate to severe disability from their migraine.
Primary Outcomes
Using the chi-square test and a CES-D score threshold of at least 16, the proportion of patients with focal epilepsy who screened positive for depressive symptoms was higher in the group with migraine than in the group without migraine (35.2% vs. 22.7%, p=0.031) (Table 2, Figure 1). Using linear regression with gender, age, and migraine as predictors and CES-D score as the dependent variable, only migraine was significant (standardized β=0.13, p=0.018), not age or gender. Using the chi-square test and a GAD-7 threshold of at least 10, the proportion of patients with focal epilepsy who screened positive for anxiety symptoms was higher in the group with migraine than in the group without migraine (16.9% vs. 4.8%, p<0.001) (Table 2, Figure 1). In a linear regression with gender, age, and migraine as predictors and GAD-7 as the dependent variable, only age was significant (standardized β=−0.11, p=0.048). Comorbid migraine was not associated with the presence or absence of CSSR-S suicidal ideation or behavior (Table 2).
| Variable | Total number of participants with data available | All participants (N=349) | Epilepsy patients without migraine (N=275) | Epilepsy patients with migraine (N=74) | pb | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |||
| CES-D score ≥16 | 341 | 86 | 25.3 | 61 | 22.7 | 25 | 35.2 | 0.031 |
| GAD-7 score ≥10 | 341 | 25 | 7.4 | 13 | 4.8 | 12 | 16.9 | <0.001 |
| C-SSRS ideation | 337 | 76 | 22.6 | 54 | 20.5 | 22 | 30.1 | 0.080 |
| C-SSRS behavior | 337 | 20 | 5.9 | 13 | 4.9 | 7 | 9.6 | 0.140 |
| C-SSRS ideation or behavior | 337 | 76 | 22.6 | 54 | 20.5 | 22 | 30.1 | 0.080 |
a
CES-D=Center for Epidemiologic Studies Depression Scale; C-SSRS=Columbia-Suicide Severity Rating Scale; GAD-7=7-item Generalized Anxiety Disorder scale.
b
Chi-square test was used. Bold indicates statistical significance.
FIGURE 1. Scores on the Center for Epidemiologic Studies Depression (CES-D) and 7-item Generalized Anxiety Disorder (GAD-7) scales among patients with new-onset focal epilepsy with and without migrainea
aThe box plots show CES-D (panel A) and GAD-7 (panel B) scores for patients with epilepsy without and with migraine.
Discussion
There were more women in the group with migraine, which was expected because the prevalence of migraine is higher among women (24). However, this difference did not play a role in the findings. Among our sample of people with newly diagnosed focal epilepsy and migraine, the age at onset of headache is consistent with the age at onset of migraine in the general population (24).
This cross-sectional study of select psychiatric symptoms among patients with new-onset focal epilepsy who have or do not have comorbid migraine had two key findings: First, comorbid migraine among patients with focal epilepsy is associated with depression symptoms. Second, the two groups had no difference in terms of anxiety symptoms or suicidality.
The prevalence of depression among adults in the United States in 2017 was 7.1%. Depression is the most common psychiatric condition comorbid with epilepsy and one of the most common comorbid with migraine (3, 25, 26). Although the reported prevalence of depression among people with migraine is highly variable, ranging from 8.6% to 47.9%, several studies have shown that patients with migraine are 2.5 times more likely to have depression than people without migraine (3). Although the reported prevalence of depression among people with epilepsy is also highly variable, ranging from 11.2% to 39.0%, a large population-based study showed an odds ratio of 1.8 (95% CI=1.0, 3.1) for a lifetime episode of major depressive disorder among people with epilepsy (2). In this study, the proportion of patients with focal epilepsy without migraine who screened positive for depressive symptoms is higher than expected in the general population of people without migraine and without epilepsy. The proportion of patients with newly diagnosed focal epilepsy with comorbid migraine who screened positive for depressive symptoms is within the range observed in cohorts of people with migraine and without epilepsy, which suggests that the increased risks of developing depressive symptoms independently associated with migraine and epilepsy do not directly add up among the population of people with both migraine and epilepsy.
Potential theories for the association between comorbid migraine and depression among people with focal epilepsy include dysfunction in the serotonergic neural activities, shared pathophysiology (27, 28) with affective disorders, pain, socioeconomic status difficulties (29, 30), and shared genetics (31).
Limitations
Our study has several limitations. The study is cross-sectional, and therefore we cannot determine temporality (e.g., whether the depression might have predated the epilepsy). However, this is a population with focal epilepsy newly diagnosed within 4 months of enrollment, so the participants are known to not have a high seizure burden or long exposure to antiepileptic medications. Second, for this specific analysis of the data, we used validated screening instruments for depression and anxiety rather than clinical diagnoses. Third, we had no data on headache frequency, headache medications, seizure frequency and localization, and seizure medications. Medication use might be a confounder in the association between comorbid depression and migraine among people with new-onset focal epilepsy. For example, providers might be more inclined to prescribe topiramate than lamotrigine for new-onset focal epilepsy to patients with comorbid migraine. However, the participants were assessed within 4 months of focal epilepsy diagnosis, so as noted earlier, they did not have long-term exposure to any antiepileptic medications for seizure treatment. Although to our knowledge the literature has no guidelines for the treatment of epilepsy with comorbid migraine, therapeutic independence when treating two comorbid conditions presents many advantages, such as optimal treatment of both conditions and lower risk of unacceptable side effects. Focal epilepsy localization is another potential confounder for which we do not have data. For example, temporal lobe epilepsy is thought to be most likely to be associated with depression.
Future Studies
Future work might address the potential benefit of systematically screening people with focal epilepsy and migraine for depression and study pharmacological and nonpharmacological management of depression in people with focal epilepsy and migraine. For example, progressive muscle relaxation therapy has been shown to be beneficial to people with epilepsy and to people with migraine (32, 33), and it might be helpful in treating the neuropsychiatric symptoms of patients with epilepsy and comorbid migraine. Third, future studies might assess whether there is an association between postictal headaches and psychiatric symptoms. Fourth, another direction would be to look at clinical outcomes to assess whether comorbid migraine and a potentially higher risk of depressive symptoms are associated with a worse prognosis in people with focal epilepsy.
Conclusions
Among a sample of patients with newly diagnosed focal epilepsy, 21.2% had migraine. The patients with epilepsy and comorbid migraine reported more symptoms of depression than those without migraine. Clinicians should be alert for signs of depression among patients with epilepsy and migraine. Given the paucity of studies evaluating the relationship among epilepsy, migraine, and other associated psychiatric conditions, further studies should be performed to better assess interactions between conditions and the treatment implications.
Footnotes
Creation of the Human Epilepsy Project (HEP) was sponsored by the Epilepsy Study Consortium. Funding for HEP was received from industry, philanthropy, and foundations (UCB Pharma, Eisai, Pfizer, Lundbeck, Sunovion, The Andrews Foundation, The Vogelstein Foundation, Finding A Cure for Epilepsy and Seizures [FACES], and Friends of Faces). The funders of HEP had no role in the design or conduct of this study; collection, management, analysis, or interpretation of the data; preparation of the manuscript; or decision to submit the manuscript for publication.
The authors thank all of the Human Epilepsy Project investigators and patients who participated in the study.
References
1.
Hesdorffer DC: Comorbidity between neurological illness and psychiatric disorders. CNS Spectr 2016; 21:230–238
2.
Tellez-Zenteno JF, Patten SB, Jetté N, et al: Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48:2336–2344
3.
Minen MT, Begasse De Dhaem O, Kroon Van Diest A, et al: Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 2016; 87:741–749
4.
Hesdorffer DC, Hauser WA, Annegers JF, et al: Major depression is a risk factor for seizures in older adults. Ann Neurol 2000; 47:246–249
5.
Antonaci F, Nappi G, Galli F, et al: Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain 2011; 12:115–125
6.
Jetté N, Amoozegar F, Patten SB: Depression in epilepsy, migraine, and multiple sclerosis: epidemiology and how to screen for it. Neurol Clin Pract 2017; 7:118–127
7.
Kanner AM, Byrne R, Chicharro A, et al: A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009; 72:793–799
8.
Kanner AM, Schachter SC, Barry JJ, et al: Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 2012; 24:156–168
9.
Breslau N, Schultz LR, Stewart WF, et al: Headache and major depression: is the association specific to migraine? Neurology 2000; 54:308–313
10.
Smitherman TA, Davis RE, Walters AB, et al: Anxiety sensitivity and headache: diagnostic differences, impact, and relations with perceived headache triggers. Cephalalgia 2015; 35:710–721
11.
Hesdorffer DC, French JA, Posner K, et al: Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials. Epilepsia 2013; 54:879–887
12.
Friedman LE, Gelaye B, Bain PA, et al: A systematic review and meta-analysis of migraine and suicidal ideation. Clin J Pain 2017; 33:659–665
13.
Human Epilepsy Project. http://www.humanepilepsyproject.org
14.
Cosco TD, Prina M, Stubbs B, et al: Reliability and validity of the Center for Epidemiologic Studies Depression Scale in a population-based cohort of middle-aged U.S. adults. J Nurs Meas 2017; 25:476–485
15.
Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1(3):385–401
16.
Seo JG, Cho YW, Lee SJ, et al: Validation of the Generalized Anxiety Disorder–7 in people with epilepsy: a MEPSY study. Epilepsy Behav 2014; 35:59–63
17.
Seo JG, Park SP. Validation of the Generalized Anxiety Disorder–7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 2015; 16:97
18.
Kroenke K, Spitzer RL, Williams JB, et al: Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146:317–325
19.
Posner K, Brown GK, Stanley B, et al: The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168:1266–1277
20.
Stewart WF, Lipton RB, Celentano DD, et al: Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267:64–69
21.
Lipton RB, Stewart WF, Diamond S, et al: Prevalence and burden of migraine in the United States: data from the American Migraine Study, II. Headache 2001; 41:646–657
22.
Headache Classification Committee of the International Headache Society: The International Classification of Headache Disorders, 3rd ed. Cephalalgia 2018; 38:1–211
23.
Stewart WF, Lipton RB, Kolodner KB, et al: Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000; 88:41–52
24.
Lipton RB, Bigal ME: Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45(Suppl 1):S3–S13
25.
Kanner AM: Depression in epilepsy: a neurobiologic perspective. Epilepsy Curr 2005; 5:21–27
26.
National Institute of Mental Health: Mental health information, statistics: major depression. Bethesda, Md, National Institute of Mental Health, 2019. https://www.nimh.nih.gov/health/statistics/major-depression.shtml
27.
Wang SJ: Migraine and suicide. Expert Rev Neurother 2007; 7:1069–1071
28.
Pompili M, Serafini G, Di Cosimo D, et al: Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 2010; 6:81–91
29.
Fuller-Thomson E, Schrumm M, Brennenstuhl S: Migraine and despair: factors associated with depression and suicidal ideation among Canadian migraineurs in a population-based study. Depress Res Treat 2013; 2013:401487
30.
Fuller-Thomson E, Hamelin GP, Granger SJ: Suicidal ideation in a population-based sample of adolescents: implications for family medicine practice. ISRN Family Med 2013; 2013:282378
31.
Anttila V, Bulik-Sullivan B, Finucane HK, et al: Analysis of shared heritability in common disorders of the brain. Science 2018; 360:eaap875
32.
Haut SR, Lipton RB, Cornes S, et al: Behavioral interventions as a treatment for epilepsy: a multicenter randomized controlled trial. Neurology 2018; 90:e963–e970
33.
Minen MT, Adhikari S, Seng EK, et al: Smartphone-based migraine behavioral therapy: a single-arm study with assessment of mental health predictors. NPJ Digit Med 2019; 2:46
Information & Authors
Information
Published In
History
Received: 9 July 2021
Accepted: 16 August 2021
Published online: 28 December 2021
Published in print: Spring 2022
Keywords
Authors
Funding Information
Dr. Kanner has received honoraria from GW Laboratories for a lecture given to their staff. Dr. Sperling has received research contracts between Thomas Jefferson University and Cavion, Cerevel, Eisai, Engage Therapeutics, Medtronic, Neurelis, SK Life Sciences, Takeda, UCB Pharma, and Xenon and receives consulting with fees to Thomas Jefferson University from Medtronic and speaking fees from Eisai, Medscape, NeurologyLive, and Projects in Knowledge. Dr. French receives New York University (NYU) salary support from the Epilepsy Foundation and for consulting work or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Aeonian/Aeovian, Anavex, Arvelle Therapeutics, Athenen Therapeutics/Carnot Pharma, Axovant, Biogen, BioXcel Therapeutics, Blackfynn, Cerebral Therapeutics, Cerevel, Crossject, CuroNZ, Eisai, Encoded Therapeutics, Engage Therapeutics, Epiminder, Epitel, Fortress Biotech, Greenwich Biosciences, GW Pharma, Ionis, Janssen Pharmaceutica, Knopp Biosciences, Lundbeck, Marinus, Merck, NeuCyte, Neurocrine, Otsuka Pharmaceutical Development, Ovid Therapeutics, Passage Bio, Pfizer, Praxis, Redpin, Sage, SK Life Sciences, Stoke, Sunovion, Supernus, Takeda, UCB, Xenon, Xeris, and Zogenix; she has also received research grants from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, Pfizer, SK Life Sciences, Sunovion, UCB, Xenon, and Zogenix, as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and National Institute of Neurological Disorders and Stroke; she serves on the editorial board of Lancet Neurology and Neurology Today; she is Chief Medical/Innovation Officer for the Epilepsy Foundation, for which NYU receives salary support; and she has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from Arvelle Therapeutics, Biogen, Cerevel, Engage, Epilepsy Foundation, Epilepsy Study Consortium, Lundbeck, NeuCyte, Inc., Otsuka, Sage, UCB, Xenon, and Zogenix. Dr. O’Brien has received research support funding from Biogen, Eisai, Praxis Precision Medicine, UCB, and Zynerba. The other authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).